Meeting
2020 ASCO Virtual Scientific Program
HER2 status and prediction of extended endocrine benefit with breast cancer index (BCI) in HR+ patients in the adjuvant tamoxifen: To offer more? (aTTom) trial.
Authors
John Bartlett
Ontario Institute for Cancer Research, Toronto, ON, Canada
John Bartlett , Dennis C. Sgroi , Kai Treuner , Yi Zhang , Tammy Piper , Ranelle C. Salunga , Ikhlaaq Ahmed , Lucy Doos , Sarah Thornber , Karen J. Taylor , Elena F. Brachtel , Sarah Pirrie , Catherine A. Schnabel , Daniel William Rea
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00003678
Citation
J Clin Oncol 38: 2020 (suppl; abstr 522)
DOI
10.1200/JCO.2020.38.15_suppl.522
Abstract #
522
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers.
First Author: Julia Foldi
Poster
2015 ASCO Annual Meeting
Evaluation of the Breast Cancer Index in patients with HER2+/HR+ breast cancer for risk of late recurrence and potential extended endocrine benefit.
First Author: Ruth O'Regan
Poster
2013 ASCO Annual Meeting
The prospective MammaPrint MINT (Multi-Institutional Neo-adjuvant Therapy) study.
First Author: Charles E. Cox
Poster
2013 ASCO Annual Meeting
OPTIMA prelim: Optimal personalized treatment of early breast cancer using multiparameter tests.
First Author: Rob Stein